Table 1 Baseline characteristics of the 169 patients with antineutrophil cytoplasmic antibody-associated vasculitis
|  | All (n = 169) | MPA (n = 105) | GPA (n = 36) | EGPA (n = 25) |
|---|---|---|---|---|
Male/female, n/n | 65/104 | 45/60 | 14/22 | 6/19 |
Age, years | 71 (61–78) | 73 (66–78) | 69 (60–79) | 60 (46–70) |
MPO-ANCA-positive | 137 (81.1%) | 103 (98.1%) | 22 (61.1%) | 9 (36%) |
PR3-ANCA-positive | 20 (12.2%) | 4 (4.0%) | 15 (41.7%) | 1 (4.2%) |
ANCA-negative | 18 (10.7%) | 1 (1.0%) | 1 (2.8%) | 16 (64%) |
WBC, count/μl | 9400 (7000–14,300) | 8500 (6200–12,300) | 9950 (7825–14,050) | 19,200 (15,090–27,700) |
Serum creatinine, mg/dl | 0.92 (0.66–2.43) | 1.41 (0.81–3.56) | 0.71 (0.61–1.24) | 0.59 (0.44–0.76) |
eGFR, ml/minute/1.73 m2 | 50 (17–74) | 34 (12–61) | 65 (41–75) | 81 (68–107) |
Disease activity and organ involvement | ||||
 BVAS score | 16 (12–21) | 15 (12–19) | 19 (12–24) | 17 (14–20) |
 BVAS chest positive | 75 (44.4%) | 43 (41%) | 17 (47.2%) | 15 (60%) |
 BVAS renal positive | 120 (71%) | 92 (87.6%) | 23 (63.9%) | 4 (16%) |
Disease severity | ||||
 EUVAS disease severity, L/ES/Ge/Se, n | 5/37/96/31 | 2/27/52/24 | 3/7/23/3 | 0/1/20/14 |
 RPGN clinical grading, I/II/III/IV, n | 40/86/38/5 | 18/54/28/5 | 8/21/7/0 | 14/9/2/0 |
 Five-Factor Score, ≤ 1/2/≥ 3, n | 67/57/45 | 18/43/44 | 29/7/0 | 20/4/1 |
Outcomes at 6Â months | ||||
 Clinical remission (BVAS score = 0) | 121/157 (77.1%) | 71/95 (74.7%) | 28/35 (80%) | 19/24 (79.2%) |
 ESRD | 15/157 (9.6%) | 14/95 (14.7%) | 1/35 (2.9%) | 0/24 (0.0%) |